A Phase 2 clinical trial in Spinal-muscular-atrophy patients.
Latest Information Update: 03 Mar 2025
Price :
$35 *
At a glance
- Drugs Apitegromab (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms OPAL
- 27 Feb 2025 According to a Scholar Rock media release, company plans to initiate Phase 2 OPAL clinical trial in SMA patients under two years of age in 3Q 2025.
- 20 Jan 2025 New trial record
- 08 Jan 2025 According to a Scholar Rock media release, the company plans Initiate this study in mid-2025.